Faster Cardiac Answers with High‑Sensitivity Troponin
SAN DIEGO, Feb. 19, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL), a global leader of in vitro diagnostics, has released episode 56 of its Science Bytes podcast, featuring Dr. Lindy Carlstrom, Global Medical Affairs Manager for Acute Care. In this episode, Carlstrom and host Josh Casey discuss how high-sensitivity troponin (hs troponin) is transforming early cardiac diagnosis and improving emergency department efficiency.
Key Insights
- Faster answers when time matters: hs troponin detects cardiac injury earlier than traditional assays, enabling quicker diagnosis and reducing time spent in the emergency department
- Precision that clinicians can trust: With tight reproducibility at low troponin levels, hs troponin helps clinicians distinguish true myocardial injury from analytical noise
- Safer, accelerated pathways: Shortened serial testing intervals (0/1‑ or 0/2‑hour protocols) support rapid rule‑out of heart attacks and speed up patient flow
- More equitable care: Sex‑specific cutoffs and higher accuracy help ensure more consistent diagnosis across diverse patient groups
- Broader potential ahead: Emerging research is exploring new applications in cardio‑oncology, perioperative care and long‑term risk prediction
Episode 56 highlights how combining precision diagnostics with clinical context supports faster, more confident decisions, and ultimately better outcomes for patients with suspected cardiac events.
Listen to the QuidelOrtho Science Bytes podcast on major streaming platforms or at: https://www.quidelortho.com/global/en/resources/podcasts/quidelortho-science-bytes.
About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (NASDAQ:QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@QuidelOrtho.com
Media Contact:
D. Nikki Wheeler
Senior Director, Corporate Communications
Media@QuidelOrtho.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/faster-cardiac-answers-with-highsensitivity-troponin-302692081.html
SOURCE QuidelOrtho Corporation